Skip to main content

Illumina guidance

  • ILMN · Nasdaq
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$198.09+0.05%Close 17 Nov 2026 · Market value $30.17B

In its results release of 29 Oct 2026 (Q3 FY2026), Illumina gave 1 forecast in figures, among them organic revenue growth of at least +4% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
Organic revenue growthFY2026At least +4%Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$4.60B to $4.64BRaised once—To come
Revenue growthFY2026+4% to +6%Given once—To come
Organic revenue growthFY2026At least +4%Given once—To come
EPS · AdjustedFY2026$5.30 to $5.40Raised once—To come
Operating margin · AdjustedFY202623.4% to 23.6%Raised once—To come

ILMN in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.